GDTC Short Volume
CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $12.1M, listed on NASDAQ, employing roughly 42 people, carrying a beta of 0.02 to the broader market. CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. Led by Chee Kong Choo, public since 2023-04-14.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-07-16
- Short Volume
- 1.6K
- Total Volume
- 2.1K
- Short %
- 76.04%
- 30-Day Avg Short %
- 36.39%
Showing 30 days of FINRA short volume data for CytoMed Therapeutics Limited.
Learn how short volume is reported and how to read the data →
Frequently asked GDTC short volume questions
- What is the daily GDTC short volume?
- As of Jul 16, 2026, CytoMed Therapeutics Limited (GDTC) short volume is 1.6K shares against 2.1K total reported volume, or 76.04% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is GDTC short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does GDTC short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.